AVALO THERAPEUTICS, INC. Deferred Tax Liabilities, Gross
AVALO THERAPEUTICS, INC. (AVTX) had Deferred Tax Liabilities, Gross of $1.68 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-23
- 2025-12-31: Deferred Tax Liabilities, Gross $1.68M.
- 2024-12-31: Deferred Tax Liabilities, Gross $1.43M.
- 2018-12-31: Deferred Tax Liabilities, Gross $160.47K.
- 2017-12-31: Deferred Tax Liabilities, Gross $358.84K; Deferred Tax Liabilities, Gross as first filed $894.50K.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $1.68M 10-K · filed 2026-03-23 | |
| 2024-12-31 | $1.43M 10-K · filed 2026-03-23 | |
| 2018-12-31 | $160.47K 10-K · filed 2019-03-18 | |
| 2017-12-31 | $358.84K 10-K · filed 2019-03-18 | $894.50K 10-K · filed 2018-04-02 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |